Big pharma, Partnering, Pharma

AstraZeneca and Orca Pharma in ROR gamma inhibitor pact

Posted on 26 February 2015

Tags: , ,

Orca Pharmaceuticals and AstraZeneca announced a three year collaboration to develop inhibitors of retinoic acid–related orphan nuclear receptor gamma (RORγ).

Inhibitors of this receptor are believed to have potential against a wide range of autoimmune diseases for which there is currently no safe, orally available and effective treatment.

AstraZeneca will gain access to RORγ inhibitors developed by Orca Pharmaceuticals and will integrate these into its in-house programme.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
  • CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time


Working together, scientists from AstraZeneca and Orca Pharmaceuticals will identify lead compounds from this programme for progression and characterise the autoimmune condition to which the lead compounds are best suited.

Orca Pharmaceuticals will receive an upfront and milestone payments from AstraZeneca dependent on the success of their RORγ inhibitors in the programme with a potential total value of $122.5 million.

AstraZeneca has the option to acquire the Orca compounds at the end of the collaboration.

For further deal information visit Current Agreements (subscription required)


Scorecard: Top partnering deals by value in 2015

View: Top pharmaceutical companies

View: Top biotech companies

Reports: Browse our extensive deal making report portfolio

Print Friendly, PDF & Email

Leave a Reply